2 days ago
Gain Therapeutics price target lowered to $6 from $7 at Roth Capital
Roth Capital lowered the firm's price target on Gain Therapeutics (GANX) to $6 from $7 and keeps a Buy rating on the shares after meeting with its CEO to discuss the company's Phase 1b study evaluating lead candidate GT-02287 in Parkinson's disease. The CSF biomarker data expected in Q4 makes most sense 'to gain preliminary conviction' as it better capitulates pathological changes associated with iPD and GBA1-PD vs. serum biomarker analysis, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
